Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
UCB Japan Recalls Cimzia Over Needle Retraction Defect
UCB Japan is voluntarily recalling certain lots of its TNF-alpha inhibitor Cimzia 200 mg AutoClicks (certolizumab pegol) for SC Injection due to a needle retraction defect. The company identified the defect in March after finding that the needle did not…
To read the full story
BUSINESS
- UCB Japan Recalls Cimzia Over Needle Retraction Defect
October 16, 2026
- AstraZeneca Releases Breztri 14.4 for Asthma in Japan
October 16, 2026
- Takeda’s Narcolepsy Med Orzeyful Now Available in Japan, China
October 15, 2026
- JCR’s Izcargo Reels in Conditional Approval in Kuwait
October 15, 2026
- Nxera Licenses Quviviq to Taiwan’s Synmosa in 8 APAC Markets
October 15, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…